REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

19/02/2020 16:20

RNS Number : 5160D
GlaxoSmithKline PLC
19 February 2020
 


GlaxoSmithKline plc (the 'Company')
 
Deferred Annual Bonus Plan Awards
On 14 February 2020, the Company granted awards to the Executive Directors and other Persons Discharging Managerial Responsibilities ('PDMRs') listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.
Executive Directors are required to defer 50% of any bonus earned into Ordinary Shares or American Depositary Shares ('ADSs') for a period of three years. Other members of the Corporate Executive Team are required to defer 25% of any bonus earned into Ordinary Shares or ADSs for the same period. 
With effect from 2018, DABP Matching Awards are no longer granted.  
The awards have been granted as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.
The numbers of Ordinary Shares and ADSs shown below are exclusive of dividend reinvestment that will accrue during the deferral period.
 
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan.  




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814


52,169


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr H Barron




b)


Position/status


Chief Scientific Officer and President, R&D




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$43.78


30,547


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


16,462


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP, Human Resources




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


6,786


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP & General Counsel




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


9,679


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics and Compliance




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


5,116


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications & CEO Office




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
 


4,129


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr I Mackay




b)


Position/status


Chief Financial Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


35,223


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$43.78


5,626


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


15,796


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


11,581


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


8,202


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$43.78


5,711


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.814
.


6,691


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-02-14




f)


Place of the transaction
 


N/A




 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQKLFFBLLFBBE